Boehringer Ingelheim Signs a License Agreement with Yuhan Corporation to Develop Dual Agonist for Nonalcoholic Steatohepatitis

 Boehringer Ingelheim Signs a License Agreement with Yuhan Corporation to Develop Dual Agonist for Nonalcoholic Steatohepatitis

Boehringer Ingelheim Signs a License Agreement with Yuhan Corporation to Develop Dual Agonist for Nonalcoholic Steatohepatitis

Shots:

  • Yuhan to receive $40M as upfront & near-term payment and up to $830M milestones and royalties on sales. BI focuses to develop NASH treatment targeting key drivers of the disease i.e, steatosis, inflammation and fibrosis
  •  The focus of the collaboration is to develop dual agonist combining GLP-1 and FGF21 activity in a single molecule for the treatment of NASH & other liver diseases and to expand BI’s NASH portfolio
  • The dual agonist is a fusion protein utilizing the long-acting HyFc technology of Genexine, developed by Yuhan Corporation. Additionally, the collaboration of the companies is Korea’s first out-licensing of biologics targeting NASH

Click here to read full press release/ article | Ref: Boehringer Ingelheim | Image: MT Production

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post